, Susan Waserman, MD MSc FAAAAI 1 , and Parameswaran K. Nair, MD PhD FRCP FRCPC 1,2 ; 1 McMaster University, Hamilton, ON, Canada, 2 St. Joseph's Healthcare, Hamilton, ON, Canada. RATIONALE: Some patients with severe asthma on high-dose inhaled/ systemic corticosteroid, with normal serum immunoglobulins, are prone to recurrent respiratory infections. We hypothesized that they may have reduced airway immunoglobulins (Ig). The objectives of this study are to: 1) compare Ig levels in serum and sputum in such patients compared to normal healthy controls and 2) to compare the effects of subcutaneous (SC) and intravenous (IV) Ig replacement on sputum and serum Ig levels and clinical outcomes. METHODS: All Ig classes were measured by Multiplex assay (Eve Technologies, Alberta) in serum and cell-free sputum supernatants in severe asthmatics with > _2 prior episodes of neutrophilic/infective bronchitis (total sputum cell count > _25310 6 cells/g and neutrophils >79% and pathogens identified on bacterial culture) (n524), and in healthy controls (n56). Measurements were repeated in a subset of patients 3 months after IV or SC Ig therapy. RESULTS: Overall, Ig levels (across all classes) were higher in serum than in sputum. Igs were not lower in sputum in the neutrophilic bronchitis patients compared to controls. In fact, IgG 2 (3.67x10 3 vs 1.21x10 3 ng/mL, p<0.03) and IgG 4 (83.86 vs 13.90 ng/mL, p<0.05) levels were higher than in healthy controls. Greater improvements in sputum IgG 1 (p50.06) and sputum IgA (p50.01) were seen following IVIg compared to SCIg (n59), associated with less episodes of infective bronchitis during the 6-month follow-up (2.3 vs 0.8, P<0.03, paired t-test). CONCLUSIONS: Ig replacement by IV may be more effective than SC in patients with recurrent neutrophilic bronchitis. A larger randomized clinical trial is warranted.
688
Off-label use of omalizumab in pediatric anaphylaxis Esozia Arroabarren, Maria J. Alvarez-Puebla, and Marta Anda; Complejo Hospitalario de Navarra, Pamplona, Spain. RATIONALE: Off-label uses of drugs require a careful assessment of benefit-risk ratio. Omalizumab's indications include severe asthma and chronic urticaria in patients older than 6 years. METHODS: We describe a group of children receiving omalizumab as an off-label use for anaphylaxis and their clinical response. . Afterwards, a patient developed 2 anaphylaxis (1 during SOTI induction and the other during maintenance phase). ERT has been administered for 18 months so far and the SOTI has been tolerated by the other 3 patients. Omalizumab's doses/frequency have been diminished in 2 out of 5 patients, and increased in another one. CONCLUSIONS: Omalizumab's addition allowed continuing SOTI/ desensitazation procedures in high risk patients, reducing the number of anaphylaxis episodes. Despite its administration protective measures such as anaphylaxis management plans, cofactors avoidance and rescue medication are to be maintained in such patients. As our sample includes very young children, we must be aware there is no knowledge about our choice's future consequences.
689
Regulation of allergic airway inflammation through CD4 T cell plasticity Donald Cook, PhD, Greg S. Whitehead, and Seddon Thomas, PhD; NIEHS/NIH, RTP, NC. RATIONALE: LPS acts as a potent adjuvant in the airway to promote Th2 and Th17 immune responses to inhaled allergens. We investigated whether the airway neutrophilia triggered by inhaled LPS contributes to its adjuvant activity. METHODS: Mice were treated with a neutrophil-depleting antibody (1A8) or with an isotype control (IC) antibody, then sensitized to ovalbumin (OVA) using small amounts of LPS as the adjuvant. Allergic airway inflammation was subsequently elicited by exposing the mice to aerosolized OVA on either one occasion, or on five consecutive days. Some mice received adoptive transfer of na€ ıve, OVA-specific, IL-17 fate mapping CD4 T cells prior to allergic sensitization. Flow cytometry was used to sort progeny of these cells post-allergen challenge for RNA extraction and gene profiling. RESULTS: Levels of TGF-beta in the airway during allergic sensitization were reduced by prior neutrophil depletion. IL-17 in regional lymph nodes and allergic responses to single subsequent challenge were unaffected by neutrophil depletion. However, this treatment was associated with increased allergic inflammation following multiple OVA challenges. Analysis of fate mapped Th17 cells revealed that after several OVA challenges, Th17 cells acquired a more regulatory phenotype, and that this shift was less apparent in mice that had undergone neutrophil depletion prior to sensitization. CONCLUSIONS: LPS-induced neutrophils produce TGF-beta that enhances the transition of Th17 cells to a more regulatory phenotype upon continued allergen exposure. These findings suggest that modulating the plasticity of Th17 cells might be an effective strategy to control allergic asthma.
